DPH.Lライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (16 1月 2024 @ 02:38):

Stats
本日の出来高	192 108
平均出来高	1.36M
時価総額	4.40B
EPS	£0 ( 2024-02-25 )
Last Dividend	£12.50 ( 2023-03-09 )
Next Dividend	£0 ( N/A )
P/E	-154.64
ATR14	£15.19 (0.39%)

ボリューム相関

長: 0.33 (neutral)

短: 0.95 (very strong)

Signal:(71.495) Expect same movement, but be aware

Dechra Pharmaceuticals 相関

10 最も正の相関
BUR.L	0.808

10 最も負の相関
DMGT.L	-0.834

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Dechra Pharmaceuticals 相関 - 通貨/商品

0.19
( neutral )

0.34
( neutral )

-0.40
( neutral )

-0.04
( neutral )

0.41
( neutral )

0.36
( neutral )

Dechra Pharmaceuticals 財務諸表

Annual	2022
収益:	£761.50M
総利益:	£426.30M (55.98 %)
EPS:	£-0.240

FY	2022
収益:	£761.50M
総利益:	£426.30M (55.98 %)
EPS:	£-0.240

FY	2022
収益:	£681.80M
総利益:	£384.80M (56.44 %)
EPS:	£0.540

FY	2021
収益:	£608.00M
総利益:	£345.90M (56.89 %)
EPS:	£0.538

Financial Reports:

No articles found.

Dechra Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£32.89 (N/A)	£12.50 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Dechra Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.80 - low (26.53%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	£1.133	2001-03-07
Last Dividend	£12.50	2023-03-09
Next Dividend	£0	N/A
Payout Date	2023-04-13
Next Payout Date	N/A
# dividends	45	--
Total Paid Out	£356.25	--
Avg. Dividend % Per Year	0.54%	--
Score	2.05	--
Div. Sustainability Score	3.80
Div.Growth Potential Score	0
Div. Directional Score	1.261	--

Next Divdend (Est)
(2024-07-08)

£12.38 Estimate 1.26 %

Dividend Stability

0.10 Bad

Dividend Score

2.05

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2001	£0	0.00%
2002	£0	0.00%
2003	£0	0.00%
2004	£0	0.00%
2005	£0	0.00%
2006	£0	0.00%
2007	£0	0.00%
2008	£0	0.00%
2009	£0	0.00%
2010	£0	0.00%
2011	£0	0.00%
2012	£0	0.00%
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£25.50	0.92%
2019	£31.60	1.51%
2020	£34.29	1.17%
2021	£40.50	1.14%
2022	£44.89	0.94%
2023	£12.50	0.48%
2024	£0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SAIN.L	Dividend King	2023-08-10	Quarterly	52	1.59%
HSL.L	Dividend Knight	2023-08-24	Semi-Annually	53	1.65%
BBH.L	Dividend Junior	2023-07-27	Semi-Annually	8	2.36%
WIN.L	Dividend Knight	2023-07-13	Annually	24	2.13%
MVI.L	Dividend Royal	2023-08-03	Quarterly	9	304.83%
DWHT.L	Dividend Knight	2023-07-06	Semi-Annually	32	0.79%
SNR.L	Dividend Knight	2023-10-12	Annually	32	0.45%
IOM.L	Dividend Knight	2023-08-17	Semi-Annually	20	2.24%
BRCK.L	Dividend Knight	2023-08-24	Semi-Annually	6	2.38%
PCFT.L	Dividend Knight	2023-08-03	Semi-Annually	11	1.80%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0366	1.500	-0.733	-1.099	[0 - 0.5]
returnOnAssetsTTM	-0.0178	1.200	-0.593	-0.711	[0 - 0.3]
returnOnEquityTTM	-0.0349	1.500	-1.499	-2.25	[0.1 - 1]
payoutRatioTTM	-1.853	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	2.85	0.800	0.735	0.588	[1 - 3]
quickRatioTTM	1.333	0.800	6.87	5.49	[0.8 - 2.5]
cashRatioTTM	0.454	1.500	8.59	10.00	[0.2 - 2]
debtRatioTTM	0.321	-1.500	4.64	-6.96	[0 - 0.6]
interestCoverageTTM	0.767	1.000	-0.827	-0.827	[3 - 30]
operatingCashFlowPerShareTTM	0.559	2.00	9.81	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.358	2.00	9.82	10.00	[0 - 20]
debtEquityRatioTTM	0.668	-1.500	7.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.564	1.000	3.93	3.93	[0.2 - 0.8]
operatingProfitMarginTTM	0.0225	1.000	-1.551	-1.551	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.126	1.000	-0.411	-0.411	[0.2 - 2]
assetTurnoverTTM	0.485	0.800	-0.0986	-0.0788	[0.5 - 2]
Total Score				3.80

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-157.77	1.000	-10.00	0	[1 - 100]
returnOnEquityTTM	-0.0349	2.50	-0.964	-2.25	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.358	2.00	9.88	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.559	2.00	9.81	10.00	[0 - 30]
payoutRatioTTM	-1.853	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	-1 577.69	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0835	1.000	-0.412	0	[0.1 - 0.5]
Total Score				-1.282

Dechra Pharmaceuticals

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.